detection of colorectal cancer

联合检测血清25羟基维生素D及肿瘤标志物在结直肠癌诊断中的应用杨晓云;刘蕊【期刊名称】《中国中西医结合外科杂志》【年(卷),期】2016(022)005【摘要】Objective To investigate the value of combined detection of serum 25(OH)D and tumor mark⁃ers in the diagnosis of colorectal cancer (CRC). Methods Serum levels of 25(OH)D, CEA, and CA19-9 were detected in 150 healthy controls and 150 cases of CRC patients. Clinical data and laboratory indexes of recruit⁃ed subjects and pathological data of CRC patients were collected. Results Serum levels of 25(OH)D in pa⁃tients with CRC (33.17 ± 15.75 nmmol/L) was lower than that in healthy controls (41.18 ± 11.59 nmmol/L),P<0.01. CEA and CA19-9 in patients with CRC [3.67(2.14,7.20) ng/mL、8.10(3.10,18.90) U/mL] were higher than those in healthy control [2.26(1.75,3.09) ng/mL、4.82(2.90,7.35) U/mL],P<0.01. Serum 25 (OH) D and CEA in patients with CRC have poor consistency (Kappa=0.174, P<0.05). Serum CEA levels of CRC patients with non-ulcer, high and middle cell differentiation, clinical stage ofⅠ~Ⅱ period and without lymph node metasta⁃sis, were significantly lower than that of CRC patients with ulcer, poorly cell differentiation, the clinical stage ofⅢ~Ⅳ period and lymph node metastasis(P<0.05), but serum 25(OH)D levels in all groups showed no statisti⁃cal difference (P>0.05). Conclusion Combineddetection of 25(OH)D, CEA and CA19-9 may has clinical application value for early diagnosis, recurrence, metastasis and prognosis of CRC.%目的：探讨联合检测血清25羟基维生素D[25(OH)D]及肿瘤标志物在结直肠癌（CRC）诊断中的应用价值。

西医肠胃科术语英文翻译以下是常见的西医肠胃科术语英文翻译：1. 胃食管反流病：Gastroesophageal Reflux Disease (GERD)2. 胃炎：Gastritis3. 消化性溃疡：Peptic Ulcer4. 胃溃疡：Gastric Ulcer5. 十二指肠溃疡：Duodenal Ulcer6. 肠道炎性疾病：Inflammatory Bowel Disease (IBD)7. 克罗恩病：Crohn's Disease8. 溃疡性结肠炎：Ulcerative Colitis9. 肠易激综合征：Irritable Bowel Syndrome (IBS)10. 肠梗阻：Intestinal Obstruction11. 肠穿孔：Intestinal Perforation12. 肛门脓肿：Perianal Abscess13. 大便失禁：Fecal Incontinence14. 便秘：Constipation15. 腹泻：Diarrhea16. 急性肠胃炎：Acute Gastroenteritis17. 肠息肉：Intestinal Polyps18. 肠癌：Colorectal Cancer19. 胃镜检查：Esophagogastroduodenoscopy (EGD)20. 肠镜检查：Colonoscopy21. X线钡剂灌肠检查：Barium Enema X-ray Examination22. 大便潜血试验：Fecal Occult Blood Test (FOBT)23. 腹部平片检查：Abdominal Plain Film Examination24. 腹部CT检查：Abdominal CT Scan25. 直肠指诊：Digital Rectal Examination (DRE)26. 内窥镜超声检查：Endoscopic Ultrasonography (EUS)27. 上消化道出血：Upper Gastrointestinal Bleeding28. 下消化道出血：Lower Gastrointestinal Bleeding29. 幽门螺杆菌检测：Helicobacter Pylori Detection30. 肝功能检查：Liver Function Tests (LFTs)31. 胃肠道营养支持：Gastrointestinal Nutrition Support32. 全肠外营养支持：Total Parenteral Nutrition (TPN)33. 内镜下息肉摘除术：Endoscopic Polypectomy34. 肛周脓肿切开引流术：Perianal Abscess Incision and Drainage35. 大肠癌根治术：Radical Resection of Colorectal Cancer36. 胃肠道转流手术：Gastrointestinal Bypass Surgery37. 人工肛门括约肌成形术：Artificial Sphincter Placement Surgery38. 肠道微生物移植：Fecal Microbiota Transplantation (FMT)39. 小肠移植：Small Bowel Transplantation40. 造口术及造口护理：Stoma Surgery and Stoma Care41. 胃癌根治术：Radical Resection of Gastric Cancer42. 胰腺炎治疗：Pancreatitis Management43. 胆道疾病治疗：Biliary Tract Disease Management44. 功能性胃肠疾病的心理治疗：Psychological Therapies for Functional Gastrointestinal Disorders (FGIDs)45. 小肠镜检与治疗：Capsule Endoscopy and Therapy for Small Bowel Conditions。

外周血microRNA-126检测在结直肠癌诊断中的意义宋红群【摘要】目的探讨外周血microRNA-126对结直肠癌的诊断意义及其与临床病理特征的相关性.方法收集我院住院的46例CRC患者作为观察组,并选取同期60例正常体检者作为对照组.采用逆转录实时荧光定量聚合酶链反应(RT-PCR)方法检测miRNA-126的表达量,分析miRNA-126与年龄、性别、肿瘤位置、分化程度、淋巴结转移、器官侵犯等临床病理特征的关系.采用ROC分析的方法研究外周血清miRNA-126相对表达量对结肠癌的诊断意义.结果观察组患者血清中的miRNA-126的相对表达量明显低于正常对照组(P＜0.05).其表达与分化程度、器官侵犯相关.受试者工作特征曲线(receiver operating characteristic curve,ROC曲线)分析显示,miRNA-126指标的曲线下面积为0.742,可作为一种辅助诊断标准.结论外周血miRNA-126在结肠癌患者中的表达明显降低,对结直肠癌的诊断具有一定的临床意义.【期刊名称】《内蒙古医学杂志》【年(卷),期】2017(049)005【总页数】4页(P513-515,封2)【关键词】miRNA-126;结直肠癌;ROC曲线【作者】宋红群【作者单位】安钢职工总医院,河南安阳 462000【正文语种】中文【中图分类】R735.37最新癌症研究报告显示，2012年全球癌症患病病例及死亡病例均有所增加，新增癌症患者近一半出现在亚洲，而中国新增癌症患者高居第一位[1]。

肺癌、结直肠癌(colorectal cancer，CRC)、前列腺癌及乳腺癌仍然是癌症死亡最常见原因，超过总体癌症死亡率的一半。

作为世界范围内高发病率及死亡率的结直肠癌，严重威胁着人类的健康。

结直肠癌的发病能够早期发现，其发病率和死亡率将会得到改善。

尽管目前的筛查手段如结肠镜检查、粪便潜血检测等多样化，但CRC的早期诊断仍较困难。

结肠癌死亡讨论病例范文英文回答：Colorectal cancer, also known as colon cancer, is a type of cancer that starts in the colon or the rectum. Itis one of the leading causes of cancer-related deaths worldwide. The death of a patient due to colorectal cancer is a tragic event that highlights the importance of early detection and effective treatment.One case that I came across involved a 55-year-old male patient who was diagnosed with stage 4 colorectal cancer. Despite undergoing surgery and chemotherapy, the cancer had metastasized to other organs, and the patient eventually succumbed to the disease. This case underscores the aggressive nature of advanced colorectal cancer and the challenges in treating it.The patient's death sparked discussions among healthcare professionals about the need for improvedscreening methods for colorectal cancer. It also highlighted the importance of educating the public about the risk factors and symptoms of the disease. Early detection is crucial in improving the chances of survival for patients with colorectal cancer.In addition, the case prompted conversations about the advancements in treatment options for advanced colorectal cancer. Immunotherapy and targeted therapies have shown promising results in some patients, but there is still a need for more effective and accessible treatments for advanced cases.Overall, the death of this patient due to colorectal cancer serves as a sobering reminder of the importance of early detection, advancements in treatment, and ongoing research efforts to combat this deadly disease.中文回答：结肠癌，也称为肠癌，是一种起源于结肠或直肠的癌症类型。

Bian C hin J Cancer (2016) 35:88 DOI 10.1186/s40880-016-0148-5Overuse of colorectal cancer screening services in the United States and its implicationsJohn Bian *AbstractAs a standard way for prevention and early detection of colorectal cancer (CRC), colonoscopy has been used for CRC screening in the United States for more than one decade. An article entitled “Assessing Colorectal Cancer Screening Adherence of Medicare Fee-For-Service Beneficiaries Age 76 to 95 Years” recently published at the Journal of Oncology Practice reports the trends in overuse of CRC screening services among average-risk elderly populations at the age of 76–95 years. Several reasons for overusing colonoscopy have been postulated, and some strategies for reducing overuse of CRC screening services have also been proposed.Keywords: Colorectal cancer, Screening services, Colonoscopy© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.A few days ago, I ran into a middle-aged lady whom I used to see frequently jogging in our neighborhood. She appeared stressed out and very tired. I was concerned and inquired about how had been with her. She told me that she had been looking after her sick mother in the past 4 months. Her mother, in her mid-eighties, had been very healthy until she was hospitalized for pneumonia last December in 2015. During her hospitalization, her doctor seemingly randomly asked whether she ever had colorectal cancer (CRC) screening tests. After told no test being done in the past, her doctor ordered a screen-ing colonoscopy while she was in the hospital. Unfor-tunately, this procedure led to perforation and forced her into a prolonged hospital stay. Her mother was still recovering from this colonoscopy-related complication.An article entitled “Assessing Colorectal Cancer Screen-ing Adherence of Medicare Fee-For-Service Beneficiaries Age 76 to 95 Years” recently published at the Journal of Oncology Practice (JOP ) by Bian et al. [1] highlighted the trends in the overuse of CRC screening services amongaverage-risk elderly populations at the age of 76–95 years from 2002 to 2010. CRC screening is an effective and a cost-effective way for reducing CRC-related death. However, these screening services, particularly colonos-copy, may carry some risks. Specifically, screening colo-noscopies may expose patients to polypectomy-related perforation and bleeding risks and to sedation-related cardiovascular and pulmonary complications. The level of these risks may also be elevated with age. As a result, after weighing in the benefit-and-risk tradeoff, the United States (US) Preventive Services Task Force (USPSTF) does not recommend routine CRC screening to indi-viduals over age 75 years at an average risk of CRC (e.g., without family history of CRC or prior polyp/adenoma history) [2]. In spite of the above explicit recommendation by the USPSTF, almost all major health insurance pro-grams in the US, such as the Medicare program (a nation-wide health insurance for the elderly age over 65 years), have continued their coverage for CRC screening of the average-risk individuals without setting upper-age limit. Consequently, there has been a growing concern about potential overuse of CRC screening services after Medi-care started coverage of all four main CRC screening modalities (including colonoscopy) in 2001 [3].Chinese Journal of Cancer*Correspondence: jbian@Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, Columbia, SC 29208, USA 495Bian C hin J Cancer (2016) 35:88This JOP article [1] reports an observational study designed for addressing this concern. This study used a 5% random non-cancer sample of Medicare fee-for-ser-vice (FFS) enrollees during 2002–2010 residing in the Surveillance, Epidemiology, and End Results (SEER) areas to construct a 9-year study cohort that included average-risk enrollees at the age of 76–95 years. The two out-comes of interest were the up-to-date status (in a given year) of adherence to overall CRC screening and to colo-noscopy (versus the other three modalities). The authors additionally analyzed a sample of average-risk enrollees at the age of 86–95 years, in which any screening services received may be deemed overuse of CRC screening ser-vices according to the USPSTF recommendation.The authors found that overall CRC screening adherence rates for studied individuals at the age of 76–95 years rose from 13.0% in 2002 to 21.4% in 2010. In 2002, 2.2% were adherent to colonoscopy, and 10.7% to the other three modalities; in 2010, the corresponding rates were 19.5 and 1.9%. The rapid rise in overall adher-ence rates may be a result of Medicare coverage policy of screening colonoscopy for average-risk beneficiaries starting in 2001, and a longer recommended screening interval of 10 years. Our additional analysis of the enroll-ees at the age of 86–95 years demonstrated that the over-all adherence rates were almost doubled from 6.7% in 2002 to 12.5% in 2010. These increases, largely driven by colonoscopy use, may represent a significant portion of overuse of CRC screening services.There are at least three plausible reasons for the observed potential overuse. First, the direct financial incentive in a Medicare FFS environment may promote over-prescription of these services. Second, because the CRC screening adherence rate has been widely used as a quality indicator for measuring performance of health-care provider, perceived higher rates may suggest higher health care quality and in turn may indirectly lead to higher payment for better performance. Third, because many providers may be overwhelmed by day-to-day busy clinical practice, particularly in primary care settings, they have little time for consulting patients about the benefits and risks of various cancer preventive services such as CRC screening. In the end, the authors cautiously offered some corresponding remedies for reducing over-use of CRC screening services: redesigning value-based payment systems, measuring age-weighted CRC screen-ing performance, and reimbursing physicians for their time discussing the trade-off of benefits and risks of screening colonoscopy.Finally, this JOP article [1] may offer some insights of using observational data for cancer health services/out-comes research in China. The dataset used in this study was longitudinal non-cancer data, paralleled to the SEER data (the cancer registry data covering a quarter of the US populations). A large body of evidence has been pub-lished from these datasets on cancer topics related to epidemiology, prevention, treatment, and survivorship. In addition, these datasets have been increasingly used for cancer health policy research [4, 5]. Undoubtedly, the evidence generated from these valuable datasets may have contributed to remarkable improvement in cancer survivorship in the US over the past four decades. As cancer death is becoming a major health burden in China [6, 7], more research that uses nationally representative cancer registry and other observational data is critically needed to monitor progresses of quality and outcomes of cancer care in China.Received: 10 June 2016 Accepted: 11 June 2016References1. Bian J, Bennett C, Cooper G, D’A lfonso A, Fisher D, Lipscomb J, Qian CN.Assessing colorectal cancer screening adherence of medicare fee-for-service beneficiaries age 76 to 95 years. J Oncol Pract. 2016;12(6):e670–80. doi:10.1200/JOP.2015.009118.2. US Preventive Services Task Force. Screening for colorectal cancer (USP-STF): US preventive services task force recommendation statement. Ann Intern Med. 2008;149:627–37.3. Goodwin JS, Singh A, Reddy N, Riall TS, Kuo YF. Overuse of screen-ing colonoscopy in the medicare populations. Arch Intern Med.2011;171:1335–43.4. Bian J, Halpern MT. Trends in outpatient breast cancer surgery amongMedicare fee-for-service patients in the United States from 1993 to 2002.Chin J Cancer. 2011;30:197–203.5. Bian J, Lipscomb J, Mello MM. Spillover effects of state mandated-benefit laws: the case of outpatient breast cancer surgery. Inquiry.2009/2010;46:433–47.6. Zhou Q, Li K, Lin GZ, Shen JC, Dong H, Gu YT, et al. Incidence trendsand age distribution of colorectal cancer by subsite in Guangzhou,2000–2011. Chin J Cancer. 2015;34(8):358–64.7. Chen WQ, Zheng RS, Zhang SW, Zeng HM, Zou XN. The incidencesand mortalities of major cancers in China, 2010. Chin J Cancer.2014;33(8):402–5.496。

癌症筛查和癌症过度诊断的相关英语作文全文共3篇示例，供读者参考篇1Cancer screening and overdiagnosis of cancer are two important topics in the field of oncology. Cancer screening aims to detect cancer at an early stage when it is more likely to be treated successfully, while overdiagnosis refers to the detection and treatment of cancers that would not have caused harm if left untreated.There are several methods for cancer screening, including mammograms for breast cancer, colonoscopies for colorectal cancer, and PSA tests for prostate cancer. While these screenings have the potential to save lives by detecting cancer at an early stage, they also have the risk of overdiagnosis. Overdiagnosis can lead to unnecessary treatment, which can have serious consequences for patients, including unnecessary surgery, radiation, and chemotherapy.One of the biggest challenges in cancer screening is finding the right balance between detecting cancers early and avoiding overdiagnosis. This requires careful consideration of the benefitsand risks of screening, as well as a clear understanding of the limitations of screening tests. It is also important for healthcare providers to communicate effectively with patients about the potential risks and benefits of screening and to involve patients in decision-making about their healthcare.In recent years, there has been increasing recognition of the problem of overdiagnosis in cancer screening. Some experts argue that the focus should shift from early detection of cancer to more personalized approaches that take into account a patient's individual risk factors and preferences. This may involve using new technologies, such as genetic testing, to identify individuals who are at higher risk of developing cancer and tailoring screening recommendations accordingly.In conclusion, cancer screening is an important tool for detecting cancer early and improving patient outcomes. However, it is also important to be aware of the risks of overdiagnosis and to take a balanced approach to screening that considers both the benefits and harms. By taking a personalized approach to screening and involving patients in decision-making, we can ensure that screening programs are effective and safe for all individuals.篇2Cancer Screening and Overdiagnosis in CancerIntroductionCancer is one of the leading causes of death worldwide, and early detection through cancer screening has been widely promoted as a means of reducing cancer mortality. However, there is growing concern about the issue of overdiagnosis in cancer screening, where individuals are diagnosed with cancers that would never have caused symptoms or harm during their lifetime. This essay will discuss the importance of cancer screening, the challenges associated with overdiagnosis, and potential solutions to address this issue.The Importance of Cancer ScreeningCancer screening aims to detect cancer in its early stages when treatment is more likely to be successful. Screening tests can detect cancer before symptoms develop, increasing the likelihood of successful treatment and survival. Examples of cancer screening tests include mammograms for breast cancer, colonoscopies for colorectal cancer, and Pap smears for cervical cancer. These screening tests have been shown to reduce cancer mortality and improve outcomes for patients when cancers are detected and treated early.Challenges of Overdiagnosis in Cancer ScreeningDespite the benefits of cancer screening, overdiagnosis is a significant concern. Overdiagnosis occurs when screening detects cancers that would never have caused harm, leading to unnecessary treatments that can have negative side effects. Overdiagnosis can result in unnecessary stress, anxiety, and financial burden for patients who receive unnecessary treatment. In addition, overdiagnosis can lead to overtreatment, where patients are treated for cancers that would never have caused symptoms or harm.Potential Solutions to Address OverdiagnosisAddressing overdiagnosis in cancer screening requires a multifaceted approach. Healthcare providers can improve the informed consent process for cancer screening, providing patients with accurate information about the risks and benefits of screening. In addition, guidelines for cancer screening can be revised to reduce unnecessary testing and follow-up procedures for low-risk individuals. Healthcare providers can also implement shared decision-making strategies to involve patients in the decision-making process about cancer screening.ConclusionCancer screening plays a crucial role in early detection and treatment of cancer, leading to improved outcomes for patients. However, overdiagnosis is a significant challenge that must be addressed to ensure that individuals receive appropriate care without unnecessary harm. By implementing strategies to reduce overdiagnosis, healthcare providers can improve the effectiveness and impact of cancer screening programs.篇3Cancer Screening and Overdiagnosis of CancerIntroductionCancer screening is crucial in early detection and prevention of cancer. It involves testing individuals for cancer before they show any symptoms. Screening tests are conducted with the aim of identifying cancer at an early stage when treatment is most effective. However, there are concerns about overdiagnosis in cancer screening, which can result in unnecessary treatments and interventions for individuals who may not have actually developed cancer. This essay explores the benefits of cancer screening, the concept of overdiagnosis in cancer, and strategies to mitigate its impact.Benefits of Cancer ScreeningCancer screening has numerous benefits in the early detection and prevention of cancer. It can help detect cancer at an early stage when it is most treatable and has a higher chance of cure. Screening tests can also identify precancerous lesions, allowing for early intervention to prevent the development of cancer. Moreover, cancer screening can reduce cancer-related mortality by detecting cancer early and enabling timely treatment. Overall, cancer screening plays a crucial role in improving outcomes for individuals at risk of developing cancer.Overdiagnosis in Cancer ScreeningOverdiagnosis refers to the detection of cancers that would never have caused symptoms or affected an individual's health. In cancer screening, overdiagnosis can result in unnecessary treatments, psychological distress for individuals, and burdens on the healthcare system. Overdiagnosis can occur due to advancements in screening technologies, increased awareness and uptake of cancer screening, and the detection of indolent or slow-growing cancers that may never progress to a clinically significant stage. It is essential to address the issue of overdiagnosis in cancer screening to ensure that individuals receive appropriate and necessary care without unnecessary harm.Strategies to Mitigate OverdiagnosisThere are several strategies to mitigate the impact of overdiagnosis in cancer screening. One approach is to develop more specific and sensitive screening tests that can distinguish between indolent and aggressive cancers. By improving the accuracy of screening tests, healthcare providers can reduce the likelihood of overdiagnosis and unnecessary treatments. Another strategy is to enhance risk stratification algorithms to identify individuals who are at higher risk of developing aggressive cancers and may benefit from screening. By tailoring screening recommendations to individual risk profiles, healthcare providers can optimize the benefits of screening while minimizing overdiagnosis. Additionally, educating healthcare providers and the public about the concept of overdiagnosis and the potential harms of unnecessary treatments can help raise awareness and facilitate shared decision-making in cancer screening.ConclusionIn conclusion, cancer screening is a valuable tool in early detection and prevention of cancer. However, overdiagnosis is a potential challenge that can lead to unnecessary treatments and interventions for individuals who may not have actuallydeveloped cancer. It is essential to understand the concept of overdiagnosis, its implications, and strategies to mitigate its impact in cancer screening. By developing more specific screening tests, enhancing risk stratification algorithms, and raising awareness among healthcare providers and the public, we can improve the effectiveness of cancer screening while minimizing the risks of overdiagnosis. Ultimately, a balanced approach that considers the benefits and potential harms of cancer screening is essential in promoting optimal health outcomes for individuals at risk of developing cancer.。

联合检验粪便及肿瘤标志物在结直肠癌诊治中的价值摘要：目的为了了解联合检验粪便和肿瘤标志物在结直肠癌诊治中的临床价值和效果。

方法选择我院中2018年3月到2019年3月收治的50例结直肠癌患者和50名健康体检者，分为实验组和参照组，均以肿瘤标志物检查、粪便检验、肿瘤标志物联合粪便检测，对比不同检测方式的敏感度情况。

结果肿瘤标志物检测结直肠癌敏感度为72%，特异度为80%，粪便检测结直肠癌敏感度52%、特异度为96%，对比肿瘤标志物联合粪便检测敏感度为94%，特异度为98%，P＜0.05，具有统计学意义。

结论联合检验粪便及肿瘤标志物检测在对结直肠癌诊治中有着比较明显的效果，具有临床推广的作用和价值。

关键词：联合检验粪便；肿瘤标志物；结直肠癌；诊治；价值The value of combined stool and tumor markers in the diagnosis and treatment of colorectal cancerAbstract: Objective To investigate the clinical value and effect of combined stool and tumor markers in the diagnosis and treatment of colorectal cancer.Methods fifty patients with colorectal cancer and 50 healthy physical examination subjects admittedto our hospital from March 2018 to March 2019 were selected and divided into experimental group and control group. Tumor marker examination, fecal test, tumor marker combined with fecal test were used to compare the sensitivity of different detection methods.Results The sensitivity and specificity of tumor markers for colorectal cancer detection were 72% and 80%, and the sensitivity and specificity of fecal markers for colorectal cancer detection were 52% and 96%, and the sensitivityand specificity of tumor markers combined with fecal detection were 94% and 98% respectively, P < 0.05, showing statistical significance.Conclusion Combined fecal and tumor markers detection has obvious effect in the diagnosis and treatment of colorectal cancer, and has the role and value of clinical promotion.Key words: Joint inspection of feces;Tumor markers;Colorectal cancer;Make a diagnosis and give treatment.The value of引言结直肠癌症是一种临床常见的下消化道恶性肿瘤，该病与人们的生活习惯和饮食习惯有关，且呈现一种逐年增长的趋势。

肿瘤标志物及血管新生因子与结直肠癌患者临床分期及肿瘤转移相关朱攀;雷蜜;高波【摘要】目的探讨肿瘤标志物及血管新生因子与结直肠癌临床分期及肿瘤转移的关系.方法用电化学发光法及酶联免疫吸附法检测结直肠癌患者及同期来医院健康体检者各100例静脉血肿瘤标志物与血管新生因子水平,并分析其与肿瘤不同TNM分期及肿瘤转移之间的关系.结果癌患者CEA、CA19-9、Ang-2、VEGF及IGF-1水平均显著高于对照组(P<0.05);不同TNM分期间CEA、CA19-9、Ang-2、VEGF及IGF-1水平有明显差异(P<0.05),随着肿瘤进展,CA19-9、Ang-2及IGF-1水平均显著升高(P<0.05),Ⅳ期CEA及VEGF水平较Ⅰ、Ⅱ与Ⅲ期显著升高(P<0.05);肿瘤转移组患者的CEA、CA19-9、Ang-2、VEGF及IGF-1水平均显著高于无转移(P<0.05).结论结直肠癌患者存在肿瘤标志物及血管新生因子水平异常升高,其指标水平检测对评估肿瘤分期及转移预测具有重要临床价值.【期刊名称】《基础医学与临床》【年(卷),期】2019(039)001【总页数】4页(P59-62)【关键词】结直肠癌;肿瘤标志物;血管新生因子;分期;转移【作者】朱攀;雷蜜;高波【作者单位】十堰市太和医院湖北医药学院附属医院检验科,湖北十堰442000;十堰市中医院检验科,湖北十堰442000;十堰市太和医院湖北医药学院附属医院检验科,湖北十堰442000【正文语种】中文【中图分类】R446.11+2结直肠癌是临床上最常见的胃肠道恶性肿瘤，其发生率及病死率呈逐渐升高趋势[1]。

结直肠癌病情转归及预后与肿瘤临床分期及转移有关，大部分早期结直肠癌患者5年生存率超过90%，局部进展期5年生存率为70%，而发生远处转移患者5年生存率仅为12%，生活质量较差[2-3]。

在中国结直肠癌早期诊断率较低，预后较差，寻找特异性的生物标志物是目前研究的重点及热点。

粪便隐血及肿瘤标志物联合检验在诊断结直肠癌中的应用分析发表时间：2019-07-22T12:36:01.073Z 来源：《兰大学报（医学版）》2019年3期作者：戴平[导读] 探讨结直肠癌实施粪便隐血及肿瘤标志物联合检验的诊断效果。

戴平湖南省常德市澧县人民医院检验科 415500摘要：目的：探讨结直肠癌实施粪便隐血及肿瘤标志物联合检验的诊断效果。

方法：将肿瘤科60例结直肠癌患者（2016年1月到2018年6月间）设为结直肠癌组，将门诊60例健康体检人员（2016年1月到2018年6月间）设为健康组，对所有人员进行粪便隐血和肿瘤标志物（CEA、CA199、CA724、TPA）检测，分析总结两组人员的检测结果、粪便隐血及肿瘤标志物联合检测对结直肠癌的诊断效果。

结果：结直肠癌组患者粪便隐血检测阳性率及血清CEA、CA199、CA724、TPA水平显著高于健康组（P<0.05）。

实施粪便隐血和肿瘤标志物联合检测的敏感性和准确率显著高于粪便隐血单独检测、肿瘤标志物单独检测（P<0.05）。

实便隐血和肿瘤标志物联合检测的特异性与粪便隐血单独检测、肿瘤标志物单独检测相比无明显差异（P>0.05）。

结论：结直肠癌实施粪便隐血及肿瘤标志物联合检验可提升诊断效果，减少漏诊和误诊状况。

Abstract: objective: to investigate the diagnostic effect of combined examination of fecal occult blood and tumor markers in colorectal cancer. Methods: 60 patients with colorectal cancer(January 2016 to June 2018) in the oncology department were set up in the colorectal cancer group, and 60 health checkups in the outpatient clinic(January 2016 to June 2018) were set up in the health group. All personnel were tested for fecal occult blood and tumor markers(CEA, CA199, CA724, TPA), and the results of the two groups 'tests were analyzed and summarized, and the results of joint detection of fecal occult blood and tumor markers were obtained. Diagnosis effect of colorectal cancer. Results: The positive rate and serum CEA, CA199, CA724 and TPA levels were significantly higher than those of healthy group(P&amp; Lt; 0.05). The sensitivity and accuracy of joint detection of fecal occult blood and tumor markers were significantly higher than that of separate detection of fecal occult blood and individual detection of tumor markers(P&amp; Lt; 0.05). There was no significant difference between the specificity of the combined detection of solid occult blood and tumor markers and the separate detection of fecal occult blood and tumor markers(P&amp; Gt; 0.05). Conclusion: The combined examination of fecal occult blood and tumor markers in colorectal cancer can improve the diagnostic effect and reduce the missed diagnosis and misdiagnosis.关键词：结直肠癌；粪便隐血；肿瘤标志物；联合检验；诊断Key words: colorectal cancer; Covered stool blood; Tumor markers; Joint inspection; diagnosis结直肠癌是当前我国较为常见的恶性肿瘤疾病，目前我国结直肠癌的发病率及致死率正逐渐升高，已经成为威胁人类生命安全的常见恶性肿瘤疾病。

联合检测血清癌胚抗原、糖链抗原19-9和C 反应蛋白对大肠癌的诊断价值高建军;索晓慧;张燕;朱晓林;刘冬青;袁虎方【摘要】目的：探讨联合检测血清癌胚抗原（carcinoembryonicantigen，CEA）、糖链抗原19-9（carbohyrate antigan 19-9，CA19-9）和炎症标志物C 反应蛋白（C-reaction protein，CRP）对大肠癌诊断的临床应用价值。

方法分别检测146例大肠癌患者、158例阑尾炎和结肠息肉患者、76例健康者 CEA、CA19-9、CRP 水平，并应用受试者工作特征（receive operating characteristic，ROC）曲线进行评价。

结果与正常对照组比较，大肠癌组和良性炎症组血清CRP、CEA 和 CA19-9水平均升高，大肠癌组 CRP 显著低于良性炎症组，但大肠癌组CEA、CA19-9明显高于良性炎症组和正常对照组，差异有统计学意义（P ﹤0.01））。

用 ROC 曲线比较 CEA、CA19-9和 CRP 区分良性炎症组和大肠癌的能力，显示 CRP 的诊断价值优于 CEA 和 CA19-9。

利用 ROC 曲线分析联合检测三者的诊断能力，其 ROC 曲线下面积（area under the ROC curve，AUC）为0.886。

结论联合检测 CEA、CA19-9和 CRP 可以弥补单项检测的不足，提高临床诊断的准确性，联合检测的准确性优于单项检测。

%Objective To assess the diagnostic value of combined detection of tumor markers carcinoembryonic antigen( CEA),carbohyrate antigen 19-9( CA19-9 ) and inflammatory marker C reactive protein( CRP)in colon cancer. Methods Serum levels of CEA,CA199 and CA125 were determined in 146 patients with colorectal cancer,158 patients with inflammatory bowel disease,colon polyp or acute appendicitis,and 76 healthy persons. And their accuracies and consistencies with the analysis of receive operatingcharacteristic(ROC)and value of Kappa were evaluated. Results Compared with the control group,the serum CRP,CA19-9 and CEA in patients with colon cancer and inflammatory bowel disease were significantly increased. The levels of CEA and CA19-9 in colon cancer group were obviously higher than those of inflammatory bowel disease group and control group. ROC was used to compare the diagnostic value of CEA,CA19-9 and CRP in discriminating benign inflammatory and colon cancer groups,indicating the diagnostic value of CRP was better than that of CEA and CA19-9. The AUC of combined detection of CEA,CA19-9 and CRP was 0. 886. Conclusion Combined detection of CEA, CA199 and CRP can help improve the diagnosis accuracy of colorectal cancer. The diagnostic accuracy was superior to individual item.【期刊名称】《河北医科大学学报》【年(卷),期】2014(000)008【总页数】4页(P904-907)【关键词】结直肠肿瘤;癌胚抗原;糖链抗原 19-9;C 反应蛋白质【作者】高建军;索晓慧;张燕;朱晓林;刘冬青;袁虎方【作者单位】河北省邯郸市第一医院检验科，河北邯郸 056002;河北省邯郸市第一医院检验科，河北邯郸 056002;河北省邯郸市第一医院检验科，河北邯郸056002;河北省邯郸市第一医院检验科，河北邯郸 056002;河北省邯郸市第一医院检验科，河北邯郸 056002;河北医科大学第四医院外三科，河北石家庄050011【正文语种】中文【中图分类】R735.34大肠癌(colon cancer)又称结直肠癌,是发生于结肠或直肠的恶性上皮性肿瘤[1]。